Plasma Concentration Studies
LY3437943
GLP-3
A 39-amino acid triple agonist peptide targeting GIP, GLP-1, and glucagon receptors, studied for metabolic regulation and body composition in clinical research. Premium Research Peptide.
Third Party Tested by Freedom Diagnostics
Technical specifications
Avoid freeze/thaw cycles. Protect from light
Lyophilized (powder)
-20°C • 24+ months
Reconstituted
2-8°C • ~30 days
Peer-reviewed research
New England Journal of Medicine
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
2023 • DOI: 10.1056/NEJMoa2301972
Jastreboff AM, et al.
The Lancet
Retatrutide for People with Type 2 Diabetes — A Phase 2 Trial
2023
Rosenstock J, et al.
Nature Medicine
Retatrutide for Metabolic Dysfunction-Associated Steatotic Liver Disease
2024
Sanyal AJ, et al.
Lancet Diabetes & Endocrinology
Effects of Retatrutide on Body Composition
2025
Coskun T, et al.
PubMed Central
Triple Agonism Based Therapies for Obesity
2025
PubMed Central
Retatrutide — A Game Changer in Obesity Pharmacotherapy
2025
PubMed Central
Efficacy and Safety of Retatrutide — Systematic Review & Meta-Analysis
2024
Eli Lilly
TRIUMPH-4 Phase 3 Trial Results
2025
Nature Cell Discovery
Structural Analysis of Incretin Receptor Agonists
2024
PubChem Database
Retatrutide Compound Information
2025
ClinicalTrials.gov
Retatrutide Clinical Trials Registry
2025
Pèptido Labs sells research peptides exclusively to qualified researchers and laboratories for in vitro and laboratory use. Please confirm before continuing.